市場調查報告書
商品編碼
972153

疼痛管理藥物市場:按藥物類別,適應症,疼痛類型:全球機會分析和行業預測(2019-2027)

Pain Management Drugs Market by Drug Class, Indication, Pain Type : Global Opportunity Analysis and Industry Forecast, 2019-2027

出版日期: | 出版商: Allied Market Research | 英文 266 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

2019年,全球止痛藥市場規模為71,431.85百萬美元。該市場預計將以3.8%的複合年增長率增長,到2027年將達到91,469.16百萬美元。疼痛是由組織損傷或疾病引起的痛苦和情感感覺。此外,多種疾病也會引起不適,包括多發性硬化症,骨關節炎,胃潰瘍,慢性關節炎,纖維肌痛,糖尿病性神經病和癌症。疼痛的長度範圍從短期急性疼痛到長期慢性疼痛。急性疼痛有時會突然發作,而慢性疼痛則是由骨骼和關節老化,神經損傷或受傷引起的。疼痛管理涉及使用特定範圍的藥物減□□輕或治療疼痛。有幾種藥物可通過多種生理機制緩解疼痛,包括靶向傷害感受器。

老年人口的增長是全球疼痛管理市場增長的主要驅動力,因為老年人往往患有關節痛和其他慢性病。例如,諸如癌症的慢性疾病的流行正在增加。根據國家癌症研究所的數據,幾乎20-50%的癌症患者患有疼痛。大約80%的晚期癌症患者患有中度至重度疼痛。此外,諸如癌症,糖尿病性神經病和骨關節炎等慢性病的流行正在推動市場增長。此外,更多的手術和更高的醫療費用有望加速市場增長。但是,藥物開發,止痛藥的過期以及止痛藥等替代品的出現拖累了市場的增長。

該報告調查了全球止痛藥物市場,並提供了市場概況以及按藥物類別,適應症,疼痛類型,地區和進入市場的公司概況的趨勢。

目錄

第1章簡介

第2章執行摘要

第3章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要成功策略
  • 頂級公司排名
  • 北美波特的五力分析
  • 政府法規
  • 市場動態
    • 促進因素
      • 慢性病發病率增加
      • 有利的監管方案
      • 老年人口增加
    • 抑制因素
      • 替代療法的可用性
      • 藥物開發
      • 處方藥專利已過期
    • 市場機會
      • 藥物開發的進展
      • 新興經濟體的不發達市場
  • 北美止痛藥價格
  • 北美疼痛管理的標準治療
  • 北美的兌換場景
  • 北美止痛藥的COVID-19效果分析

第4章全球疼痛管理藥物市場:按藥物類別

  • 概述
    • 市場規模和預測
  • NSAIDS
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家
    • 市場分析:按國家
  • 麻醉藥
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 抗驚厥
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 抗單側頭痛藥
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 抗抑鬱藥
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 鴉片類藥物
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 非麻醉型止痛藥
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家

第5章:全球疼痛管理藥物市場:按適應症

  • 概述
    • 市場規模和預測
  • 關節炎疼痛
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 神經性疼痛
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 癌症疼痛
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 慢性背痛
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 術後疼痛
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 頭疼
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 纖維肌痛
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 骨折
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 肌肉挫傷/肌肉差異
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 急性蟲滴發炎
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 其他
    • 市場規模和預測:按地區
    • 市場分析:按國家

第6章疼痛管理藥物:按疼痛類型

  • 概述
    • 市場規模和預測
  • 慢性疼痛
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 急性疼痛
    • 市場規模和預測:按地區
    • 市場分析:按國家

第7章疼痛管理藥物市場:按地區

  • 概述
    • 市場規模和預測
  • 北美
    • 主要市場趨勢,增長因素和機遇
    • 北美止痛藥市場:按國家
      • 美國止痛藥物市場:按藥物類別
      • 美國止痛藥市場:按適應症
      • 美國疼痛管理藥物市場:按疼痛類型劃分
      • 加拿大止痛藥市場:按藥物類別
      • 加拿大止痛藥市場:按適應症
      • 加拿大疼痛管理藥物市場:按疼痛類型劃分
      • 墨西哥止痛藥市場:按藥物類別
      • 墨西哥止痛藥市場:按適應症
      • 墨西哥止痛藥市場:按疼痛類型劃分
    • 北美止痛藥市場:按藥物類別
    • 北美止痛藥市場:按適應症
    • 北美疼痛管理藥物市場:按疼痛類型劃分
  • 歐洲
    • 主要市場趨勢,增長因素和機遇
    • 歐洲止痛藥市場:按國家
      • 英國止痛藥市場:按藥物類別
      • 英國止痛藥市場:按適應症
      • 英國疼痛管理藥物市場:按疼痛類型劃分
      • 德國止痛藥市場:按藥物類別
      • 德國止痛藥市場:按適應症
      • 德國疼痛管理藥物市場:按疼痛類型劃分
      • 法國止痛藥市場:按藥物類別
      • 法國止痛藥市場:按適應症
      • 法國止痛藥市場:按疼痛類型劃分
      • 意大利止痛藥市場:按藥物類別
      • 意大利止痛藥市場:按適應症
      • 意大利疼痛管理藥物市場:按疼痛類型劃分
      • 西班牙管製藥品市場:按藥品類別
      • 西班牙管製藥物市場:按指示
      • 西班牙管製藥物市場:按疼痛類型劃分
      • 其他歐洲止痛藥市場:按藥物類別
      • 其他歐洲止痛藥市場:按適應症
      • 其他歐洲止痛藥市場:按疼痛類型
    • 歐洲止痛藥物市場:按藥物類別
    • 歐洲止痛藥市場:按適應症
    • 歐洲疼痛管理藥物市場:按疼痛類型劃分
  • 亞太地區
    • 主要市場趨勢,增長因素和機遇
    • 亞太地區止痛藥市場:按國家
      • 日本止痛藥市場:按藥物類別
      • 日本止痛藥市場:按適應症
      • 日本疼痛管理藥物市場:按疼痛類型劃分
      • 中國止痛藥市場:按藥物類別
      • 中國止痛藥市場:按適應症
      • 中國疼痛管理藥物市場:按疼痛類型劃分
      • 澳大利亞止痛藥市場:按藥物類別
      • 澳大利亞止痛藥市場:按適應症
      • 澳大利亞止痛藥市場:按疼痛類型劃分
      • 印度疼痛管理藥物市場:按藥物類別
      • 印度止痛藥市場:按適應症
      • 印度疼痛管理藥物市場:按疼痛類型劃分
      • 其他亞太地區止痛藥市場:按藥物類別
      • 其他亞太地區疼痛管理藥物市場:按指示
      • 其他亞太地區疼痛管理藥物市場:按疼痛類型分類
    • 亞太疼痛管理藥物市場:按藥物類別1
    • 亞太地區止痛藥市場:按適應症
    • 亞太地區疼痛管理藥物市場:按疼痛類型分類
  • 拉美
    • 主要市場趨勢,增長因素和機遇
    • LAMEA止痛藥市場:按國家
      • 巴西止痛藥市場:按藥物類別
      • 巴西止痛藥市場:按適應症
      • 巴西止痛藥市場:按止痛類型分類
      • 沙特阿拉伯的疼痛管理藥物市場:按藥物類別
      • 沙特阿拉伯的疼痛管理藥物市場:以跡象顯示
      • 沙特阿拉伯疼痛管理藥物市場:按疼痛類型分類
      • 南非止痛藥市場:按藥物類別
      • 南非止痛藥市場:按適應症
      • 南非疼痛管理藥物市場:按疼痛類型劃分
      • LAMEA止痛藥市場的其餘部分:按藥物類別
      • LAMEA仍是止痛藥市場:按適應症
      • LAMEA止痛藥市場:按痛類型分類
    • LAMEA疼痛管理藥物市場:按藥物類別
    • LAMEA疼痛管理藥物市場:按適應症
    • LAMEA疼痛管理藥物市場:按藥物類別

第8章公司簡介

  • ABBOTT LABORATORIES
  • ELI LILY AND COMPANY
  • ENDO HEALTH SOLUTIONS, INC. (ENDO INTERNATIONAL PLC.)
  • GLAXOSMITHKLINE PLC (GSK)
  • JOHNSON & JOHNSON
  • MERCK & CO., INC.
  • MYLAN N.V.
  • NOVARTIS INTERNATIONAL AG
  • PFIZER INC.
  • PURDUE PHARMA L.P.
目錄
Product Code: A00309

Title:
Pain Management Drugs Market by Drug Class, (NSAIDS, Anesthetics, Anticonvulsant, Anti-Migraine Drugs, Antidepressant Drugs, Opioids, Non-Narcotics, and Analgesics), Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Pain, Post-Operative Pain, Migraine, Fibromyalgia, Bone Fracture, Muscle Sprain/Strain, Acute Appendicitis, and Other Indications), Pain Type (Chronic and Acute) : Global Opportunity Analysis and Industry Forecast, 2019-2027.

The global pain management drugs market was valued at $71,431.85 million in 2019, and is projected to reach $91,649.16 million by 2027, registering a CAGR of 3.8%. Pain is a distressing sensory and emotional sensation, which is caused by tissue injury or disease. Moreover, different disorders may cause discomfort, such as multiple sclerosis, osteoarthritis, stomach ulcer, chronic arthritis, fibromyalgia, diabetic neuropathy, and cancer. The length of the pain would range from acute pain for short term to chronic pain for long term. Acute pain is a sudden onset of pain when chronic pain is caused by aged bone & joint conditions, nerve damage, or injury. Pain management involves reducing or treating pain by using a given range of medications. There are several medicines available, which provide pain relief through a variety of physiological mechanisms such as targeting nociceptors.

Rise in geriatric population is the major factor that drives growth of the global pain management market, as aged people are more prone to suffer from joint pain and other chronic conditions. For instance, prevalence of chronic diseases such as cancer is on the rise. As per the National Cancer Institute, almost 20 to 50% of people with cancer suffer from pain. Around 80% of patients with advanced stage cancer suffer from moderate to severe pain. Moreover, surge in prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis propels the market growth. Furthermore, rise in number of surgical procedures and rise in healthcare expenditure are expected to fuel growth of the market. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth.

The global pain management drugs market is segmented on the basis of drug class, indication, and region On the basis of drug class, the market is categorized into nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, anticonvulsants, antimigraine agents, antidepressants, opioids, and nonnarcotic analgesics. On the basis of indication, the market is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, bone fracture, muscle sprain, acute appendicitis and others. Based on pain type, the market is segmented into chronic pain and acute pain. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the global pain management drug market along with the current trends and future estimations to elucidate the imminent investment pockets.

A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.

The market forecast is studied from 2020 to 2027

Comprehensive quantitative analysis of the industry from 2019 to 2027 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.

Extensive analysis of the key segments of the industry helps to understand the application and products of pain management used across the globe.

Key market players and their strategies have been analysed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Drug Class

  • NSAIDs
  • Anesthetics
  • Anticonvulsants
  • Anti-migraine Agents
  • Antidepressants
  • Opioids
  • Nonnarcotic Analgesics

By Indication

  • Arthritic Pain
  • Neuropathic Pain
  • Cancer Pain
  • Chronic Back Pain
  • Postoperative Pain
  • Migraine
  • Fibromyalgia
  • Bone fracture
  • Muscle sprain
  • Acute appendicitis
  • Others
  • Pain type
  • Chronic pain
  • Acute pain

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
  • KEY MARKET PLAYERS
  • Abbott Laboratories
  • Eli Lilly & Company
  • Endo Health Solutions, Inc.,
  • GlaxoSmithKline Plc.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Mylan NV.
  • Novartis AG
  • Pfizer, Inc.
  • Purdue Pharma L.P.
  • OTHER PROMINENT MARKET PLAYERS
  • Allergen Inc.
  • Bayer AG
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Sorrento Therapeutics
  • Valeant Pharmaceuticals International Inc.
  • WEX Pharmaceuticals
  • Zynerba Pharmaceuticals.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models
    • 1.4.4.Primary research

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top winning strategies
  • 3.3.Top player positioning
  • 3.4.Porter's five force analysis for North America
  • 3.5.Government regulations
  • 3.6.Market dynamics
    • 3.6.1.Drivers
      • 3.6.1.1.Rise in incidences of chronic diseases
      • 3.6.1.2.Favorable regulatory scenario
      • 3.6.1.3.Increase in geriatric population
    • 3.6.2.Restraints
      • 3.6.2.1.Availability of alternative therapies
      • 3.6.2.2.Drug exploitation
      • 3.6.2.3.Patent expiration of prescription drugs
    • 3.6.3.Opportunities
      • 3.6.3.1.Advancements in drug development
      • 3.6.3.2.Untapped markets in developing economies
  • 3.7.North America pricing for pain management drugs
  • 3.8.Standard of care for pain management in North America
  • 3.9.Reimbursement scenario in North America
  • 3.10.COVID-19 impact analysis for North America Pain Management Drugs

CHAPTER 4:GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.NSAIDS
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
    • 4.2.4.Market analysis, by country
  • 4.3.Anesthetics
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by region
    • 4.3.3.Market analysis, by country
  • 4.4.Anticonvulsants
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast, by region
    • 4.4.3.Market analysis, by country
  • 4.5.Antimigraine drug
    • 4.5.1.Key market trends, growth factors, and opportunities
    • 4.5.2.Market size and forecast, by region
    • 4.5.3.Market analysis, by country
  • 4.6.Antidepressant drugs
    • 4.6.1.Key market trends, growth factors, and opportunities
    • 4.6.2.Market size and forecast, by region
    • 4.6.3.Market analysis, by country
  • 4.7.Opioids
    • 4.7.1.Key market trends, growth factors, and opportunities
    • 4.7.2.Market size and forecast, by region
    • 4.7.3.Market analysis, by country
  • 4.8.Non-narcotic analgesics
    • 4.8.1.Key market trends, growth factors, and opportunities
    • 4.8.2.Market size and forecast, by region
    • 4.8.3.Market analysis, by country

CHAPTER 5:GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Arthritic pain
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis, by country
  • 5.3.Neuropathic pain
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market analysis, by country
  • 5.4.Cancer pain
    • 5.4.1.Market size and forecast, by region
    • 5.4.2.Market analysis, by country
  • 5.5.Chronic back pain
    • 5.5.1.Market size and forecast, by region
    • 5.5.2.Market analysis, by country
  • 5.6.Post-operative pain
    • 5.6.1.Market size and forecast, by region
    • 5.6.2.Market analysis, by country
  • 5.7.Migraine
    • 5.7.1.Market size and forecast, by region
    • 5.7.2.Market analysis, by country
  • 5.8.Fibromyalgia
    • 5.8.1.Market size and forecast, by region
    • 5.8.2.Market analysis, by country
  • 5.9.Bone fracture
    • 5.9.1.Market size and forecast, by region
    • 5.9.2.Market analysis, by country
  • 5.10.Muscle sprain/strain
    • 5.10.1.Market size and forecast, by region
    • 5.10.2.Market analysis, by country
  • 5.11.Acute appendicitis
    • 5.11.1.Market size and forecast, by region
    • 5.11.2.Market analysis, by country
  • 5.12.Others
    • 5.12.1.Market size and forecast, by region
    • 5.12.2.Market analysis, by country

CHAPTER 6:PAIN MANAGEMENT DRUGS, BY PAIN TYPE

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Chronic pain
    • 6.2.1.Market size and forecast, by region
    • 6.2.2.Market analysis, by country
  • 6.3.Acute pain
    • 6.3.1.Market size and forecast, by region
    • 6.3.2.Market analysis, by country

CHAPTER 7:PAIN MANAGEMENT DRUGS MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends, growth factors, and opportunities
    • 7.2.2.North America pain management drugs market, by country
      • 7.2.2.1.U.S. Pain management drugs market, by drug class
      • 7.2.2.2.U.S pain management drugs market, by indications
      • 7.2.2.3.U.S pain management drugs market, by pain type
      • 7.2.2.4.Canada pain management drugs market, by drug class
      • 7.2.2.5.Canada pain management drugs market, by indication
      • 7.2.2.6.Canada pain management drugs market, by pain type
      • 7.2.2.7.Mexico pain management drugs market, by drug class
      • 7.2.2.8.Mexico pain management drugs market, by indication
      • 7.2.2.9.Mexico pain management drugs market, by pain type
    • 7.2.3.North America pain management drugs market, by drug class
    • 7.2.4.North America pain management drugs market, by indication
    • 7.2.5.North America pain management drugs market, by pain type
  • 7.3.Europe
    • 7.3.1.Key market trends, growth factors, and opportunities
    • 7.3.2.Europe pain management drugs market, by country
      • 7.3.2.1.UK pain management drugs market, by drug class
      • 7.3.2.2.UK pain management drugs market, by indication
      • 7.3.2.3.UK pain management drugs market, by pain type
      • 7.3.2.4.Germany pain management drugs market, by drug class
      • 7.3.2.5.Germany pain management drugs market, by indication
      • 7.3.2.6.Germany pain management drugs market, by pain type
      • 7.3.2.7.France pain management drugs market, by drug class
      • 7.3.2.8.France pain management drugs market, by indication
      • 7.3.2.9.France pain management drugs market, by pain type
      • 7.3.2.10.Italy pain management drugs market, by drug class
      • 7.3.2.11.Italy pain management drugs market, by indication
      • 7.3.2.12.Italy pain management drugs market, by pain type
      • 7.3.2.13.Spain management drugs market, by drug class
      • 7.3.2.14.Spain Management Drugs Market, by indication
      • 7.3.2.15.Spain management drugs market, by pain type
      • 7.3.2.16.Rest of Europe pain management drugs market, by drug class
      • 7.3.2.17.Rest of Europe Pain Management Drugs Market, by indication
      • 7.3.2.18.Rest of Europe pain management drugs market, by pain type
    • 7.3.3.Europe pain management drugs market, by drug class
    • 7.3.4.Europe pain management drugs market, by indication
    • 7.3.5.Europe pain management drugs market, by pain type
  • 7.4.Asia Pacific
    • 7.4.1.Key market trends, growth factors, and opportunities
    • 7.4.2.Asia-Pacific pain management drugs market, by country
      • 7.4.2.1.Japan pain management drugs market, by drug class
      • 7.4.2.2.Japan pain management drugs market, by indications
      • 7.4.2.3.Japan Pain Management Drugs Market, by pain type
      • 7.4.2.4.China pain management drugs market, by drug class
      • 7.4.2.5.China pain management drugs market, by indications
      • 7.4.2.6.China pain management drugs market, by pain type
      • 7.4.2.7.Australia pain management drugs market, by drug class
      • 7.4.2.8.Australia pain management drugs market, by indications
      • 7.4.2.9.Australia pain management drugs market, by pain type
      • 7.4.2.10.India pain management drugs market, by drug class
      • 7.4.2.11.India pain management drugs market, by indications
      • 7.4.2.12.India pain management drugs market, by pain type
      • 7.4.2.13.Rest of Asia-Pacific pain management drugs market, by drug class
      • 7.4.2.14.Rest of Asia-Pacific pain management drugs market, by indications
      • 7.4.2.15.Rest of Asia-Pacific pain management drugs market, by pain type
    • 7.4.3.Asia-Pacific pain management drugs market, by drug Class1
    • 7.4.4.Asia-Pacific pain management drugs market, by indication
    • 7.4.5.Asia-Pacific pain management drugs market, by pain type
  • 7.5.LAMEA
    • 7.5.1.Key market trends, growth factors, and opportunities
    • 7.5.2.LAMEA pain management drugs market, by country
      • 7.5.2.1.Brazil pain management drugs market, by drug class
      • 7.5.2.2.Brazil pain management drugs market, by indication
      • 7.5.2.3.Brazil pain management drugs market, by pain type
      • 7.5.2.4.Saudi Arabia pain management drugs market, by drug class
      • 7.5.2.5.Saudi Arabia pain management drugs market, by indication
      • 7.5.2.6.Saudi Arabia pain management drugs market, by pain type
      • 7.5.2.7.South Africa pain management drugs Market, by drug class
      • 7.5.2.8.South Africa Pain Management Drugs Market, by indication
      • 7.5.2.9.South Africa pain management drugs market, by pain type
      • 7.5.2.10.Rest of LAMEA pain management drugs market, by drug class
      • 7.5.2.11.Rest of LAMEA pain management drugs market, by indication
      • 7.5.2.12.Rest of LAMEA pain management drugs market, by pain type
    • 7.5.3.LAMEA pain management drugs market, by drug Class
    • 7.5.4.LAMEA pain management drugs market, by indication
    • 7.5.5.LAMEA pain management drugs market, by drug Class

CHAPTER 8:COMPANY PROFILES

  • 8.1.ABBOTT LABORATORIES
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Product portfolio
    • 8.1.5.Business performance
  • 8.2.ELI LILY AND COMPANY
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Product portfolio
    • 8.2.5.Business performance
    • 8.2.6.Key strategic moves and developments
  • 8.3.ENDO HEALTH SOLUTIONS, INC. (ENDO INTERNATIONAL PLC.)
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product portfolio
    • 8.3.5.Business performance
  • 8.4.GLAXOSMITHKLINE PLC (GSK)
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
    • 8.4.5.Business performance
    • 8.4.6.Key strategic moves and developments
  • 8.5.JOHNSON & JOHNSON
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
    • 8.5.5.Business performance
  • 8.6.MERCK & CO., INC.
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Product portfolio
    • 8.6.5.Business performance
    • 8.6.6.Key strategic moves and developments
  • 8.7.MYLAN N.V.
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
    • 8.7.6.Key strategic moves and developments
  • 8.8.NOVARTIS INTERNATIONAL AG
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
    • 8.8.6.Key strategic moves and developments
  • 8.9.PFIZER INC.
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance
    • 8.9.6.Key strategic moves and developments
  • 8.10.PURDUE PHARMA L.P.
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
    • 8.10.5.Key strategic moves and developments

LIST OF TABLES

  • TABLE 01.PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 02.PAIN MANAGEMENT DRUGS MARKET, BY NSAIDS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 03.PAIN MANAGEMENT DRUGS MARKET, BY ANESTHETIC, BY REGION, 2019-2027 ($MILLION)
  • TABLE 04.PAIN MANAGEMENT DRUGS MARKET, BY ANTICONVULSANT, BY REGION, 2019-2027 ($MILLION)
  • TABLE 05.PAIN MANAGEMENT DRUGS MARKET, BY ANTIMIGRAINE DRUG, BY REGION, 2019-2027 ($MILLION)
  • TABLE 06.PAIN MANAGEMENT DRUGS MARKET, BY ANTIDEPRESSANT DRUGS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 07.PAIN MANAGEMENT DRUGS MARKET, BY OPIOIDS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 08.PAIN MANAGEMENT DRUGS MARKET, BY NON-NARCOTIC ANALGESICS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 09.PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 10.PAIN MANAGEMENT DRUGS MARKET, BY ARTHMITIC PAIN, BY REGION, 2019-2027 ($MILLION)
  • TABLE 11.PAIN MANAGEMENT DRUGS MARKET, BY NEUROPATHIC PAIN, BY REGION, 2019-2027 ($MILLION)
  • TABLE 12.PAIN MANAGEMENT DRUGS MARKET, BY CANCER PAIN, BY REGION, 2019-2027 ($MILLION)
  • TABLE 13.PAIN MANAGEMENT DRUGS MARKET, BY CHRONIC BACK PAIN, BY REGION, 2019-2027 ($MILLION)
  • TABLE 14.PAIN MANAGEMENT DRUGS MARKET, BY POST-OPERATIVE PAIN, BY REGION, 2019-2027 ($MILLION)
  • TABLE 15.PAIN MANAGEMENT DRUGS MARKET, BY MIGRAINE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 16.PAIN MANAGEMENT DRUGS MARKET, BY FIBROMYALGIA, BY REGION, 2019-2027 ($MILLION)
  • TABLE 17.PAIN MANAGEMENT DRUGS MARKET, BY BONE FRACTURE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 18.PAIN MANAGEMENT DRUGS MARKET, BY MUSCLE SPRAIN, BY REGION, 2019-2027 ($MILLION)
  • TABLE 19.PAIN MANAGEMENT DRUGS MARKET, BY ACUTE APPENDICITIS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 20.PAIN MANAGEMENT DRUGS MARKET, BY OTHERS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 21.PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
  • TABLE 22.PAIN MANAGEMENT DRUGS MARKET, BY CHRONIC PAIN, BY REGION, 2019-2027 ($MILLION)
  • TABLE 23.PAIN MANAGEMENT DRUGS MARKET, BY ACUTE PAIN, BY REGION, 2019-2027 ($MILLION)
  • TABLE 24.GLOBAL PAIN MANAGEMENT DRUGS MARKET REVENUE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 25.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 26.U.S. PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 27.U.S. PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019-2027 ($MILLION)
  • TABLE 28.U.S. PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
  • TABLE 29.CANADA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 30.CANADA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 31.CANADA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
  • TABLE 32.MEXICO PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 33.MEXICO PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 34.MEXICO PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
  • TABLE 35.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 36.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 37.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
  • TABLE 38.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 39.UK PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 40.UK PAIN MANAGEMENT DRUGS MARKET , BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 41.UK PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
  • TABLE 42.GERMANY PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 43.GERMANY PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 44.GERMNAY PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
  • TABLE 45.FRANCE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 46.FRNACE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 47.FRANCE PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
  • TABLE 48.ITALY PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 49.ITALY PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 50.ITALY PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
  • TABLE 51.SPAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 52.SPAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 53.SPAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
  • TABLE 54.REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 55.REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 56.REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
  • TABLE 57.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 58.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 59.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
  • TABLE 60.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 61.JAPAN PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 62.JAPAN PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019-2027 ($MILLION)
  • TABLE 63.JAPAN PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
  • TABLE 64.CHINA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 65.CHINA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019-2027 ($MILLION)
  • TABLE 66.CHINA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
  • TABLE 67.AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 68.AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019-2027 ($MILLION)
  • TABLE 69.AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
  • TABLE 70.INDIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 71.INDIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019-2027 ($MILLION)
  • TABLE 72.INDIA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
  • TABLE 73.REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 74.REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019-2027 ($MILLION)
  • TABLE 75.REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
  • TABLE 76.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 77.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 78.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
  • TABLE 79.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 80.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 81.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 82.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
  • TABLE 83.SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 84.SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 85.SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
  • TABLE 86.SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 87.SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 88.SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
  • TABLE 89.REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 90.REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 91.REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
  • TABLE 92.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 93.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 94.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
  • TABLE 95.ABBOTT: COMPANY SNAPSHOT
  • TABLE 96.ABBOTT: OERATING SEGMENT
  • TABLE 97.ABBOTT: PRODUCT PORTFOLIO
  • TABLE 98.ELI LILLY: COMPANY SNAPSHOT
  • TABLE 99.LILLY: OPERATING SEGMENTS
  • TABLE 100.ELI LILLY: PRODUCT PORTFOLIO
  • TABLE 101.ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 102.ENDO: COMPANY SNAPSHOT
  • TABLE 103.ENDO: OPERATING BUSINESS SEGMENTS
  • TABLE 104.ENDO: PRODUCT PORTFOLIO
  • TABLE 105.GSK: COMPANY SNAPSHOT
  • TABLE 106.GSK: OPERATING SEGMENTS
  • TABLE 107.GSK: PRODUCT PORTFOLIO
  • TABLE 108.J&J: COMPANY SNAPSHOT
  • TABLE 109.J&J: OPERATING BUSINESS SEGMENTS
  • TABLE 110.J&J: PRODUCT PORTFOLIO
  • TABLE 111.MERCK & CO., INC.: COMPANY SNAPSHOT
  • TABLE 112.MERCK & CO., INC.: OPERATING SEGMENTS
  • TABLE 113.MERCK & CO., INC.: PRODUCT PORTFOLIO
  • TABLE 114.MERCK & CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115.MYLAN: COMPANY SNAPSHOT
  • TABLE 116.MYLAN: OPERATING BUSINESS SEGMENTS
  • TABLE 117.MYLAN: PRODUCT PORTFOLIO
  • TABLE 118.NOVARTIS: COMPANY SNAPSHOT
  • TABLE 119.NOVARTIS: OPERATING SEGMENTS
  • TABLE 120.NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 121.PFIZER: COMPANY SNAPSHOT
  • TABLE 122.PFIZER: OERATING SEGMENT
  • TABLE 123.PFIZER: PRODUCT PORTFOLIO
  • TABLE 124.PURDUE: COMPANY SNAPSHOT
  • TABLE 125.PURDUE: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.PAIN MANAGEMENT DRUGS MARKET SEGMENTATION
  • FIGURE 02.TOP WINNING STRATEGIES, 2017-2020
  • FIGURE 03.TOP WINNING STRATEGIES: NATURE AND TYPE, 2017-2020
  • FIGURE 04.TOP WINNING STRATEGIES: BY YEAR, 2017-2020
  • FIGURE 05.TOP PLAYER POSTIONING, 2019
  • FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 08.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 09.MODEARTE THREAT OF NEW ENTRANTS
  • FIGURE 10.MODERATE COMPETITIVE OF RIVALRY
  • FIGURE 11.DRIVER, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR NSAIDS BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 13.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANESTHETIC BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 14.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANTICONVULSANT BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 15.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANTIMIGRAINE BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 16.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANTIDEPRESSANT DRUGS BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 17.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR OPIOIDS BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 18.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR NON-NARCOTIC ANALGESICS BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 19.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ARTHMITIC PAIN BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 20.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR NEUROPATHIC PAIN BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 21.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR CANCER PAIN BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 22.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR CHRONIC BACK PAIN BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 23.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR POST-OPERATIVE PAIN BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 24.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR MIGRAINE, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 25.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR FIBROMYALGIA BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 26.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR BONE FRACTURE BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 27.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR MUSCLE SPRAIN BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 28.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ACUTE APPENDICITIS BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 29.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR OTHERS BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 30.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR CHRONIC PAIN BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 31.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ACUTE PAIN BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 32.ABBOTT: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 33.ABBOTT: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 34.ABBOTT: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 35.ELI LILLY: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 36.ELI LILLY: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 37.ENDO: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 38.ENDO: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 39.GSK: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 40.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 41.GSK: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 42.J&J: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 43.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 44.J&J: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 45.MERCK & CO., INC.: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 46.MERCK & CO., INC.: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 47.MERCK & CO., INC.: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 48.MYLAN: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 49.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 50.NOVARTIS: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 51.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 52.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 53.PFIZER: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 54.PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 55.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)